Compare Gilead Sciences, Inc. (GILD) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.10B). The key difference: Gilead Sciences, Inc. is far larger — about 44.5× First Trust NASDAQ 100 Technology Index Fund's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while First Trust NASDAQ 100 Technology Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| GILD | QTEC | |
|---|---|---|
Market Cap | $182.40B | $4.10B |
Volume | 4,469,821 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $340.28 |
52-Week Low | $116.74 | $207.03 |
Typical Hold Time | 111 Days | 40 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $335.82, down 1.31% on the day. Technical indicators show a bullish trend from moving averages but caution from overbought RSI levels. The ETF provides equal-weighted exposure to the technology sector, with recent analysis highlighting its broader sector definition and liquidity advantages.
The outlook for QTEC is supported by bullish technical trends and its role in tech exposure, though overbought conditions and sector volatility present risks. Investment opportunity lies in diversified tech access, but investors face market sensitivity and valuation pressures inherent to technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
